joined I you appreciate are week, Therapeutics become have positive joining financial impact each that a the improving from what We technology, quarter. can this and work corporate quarter the everyone. pipeline, XXXX children and And the fine a afternoon, become. Good noble has Sarepta resources, a the have team we lives Sarepta Ian. mission. results even better about the that proud am of profoundly cruel we team third ago, I Sarepta can the and of I passing mission us to the you, we make rare fulfill what at doing, my suffering Thank joined passion months talent with for excited Four more still, we disease. I've of the update.
seen third reached have XX today's quarter $XX earnings revenue for all from you million net EXONDYS release, consensus. exceeding As the
again guidance. strong to Our in position a places once raise us performance
to our increasing as are million million $XXX we the today, year reported million As guidance in reported up million full $XXX from $XXX quarter. to $XXX to previous
this today. the team's leaders tenacious XX the Our today to treatment. performance as with of patients feedback received We who caregivers our as fine that EXONDYS staff experience reflects positive and of well addition patients and have treating in received receive the scientists, of many from impact XX EXONDYS execution have regularly consistently which our we about explains performance physicians feedback
us year Let's disease we if and disease five ever sharing XXXX rare for But us any Shire, put guidance Biogen. the represent that launches Vortex, successful stand outs distinction the this we ultrarare rightly let XX performance kind our of in rare guidance place greatest history. rarefied most in look will launch full will achieve EXONDYS with performance all Alexion our top in biotech context, across achieve full our if year disease launches;
positive benefit and reported The our could from methodological and development scientific our turn have of study, golodirsen quarter which this September, who patients commitment this made progress from program. the now excellence RNA advancing X% me we bringing step in our therapy. important platform our to was an data splicing DMD toward XXXX-XXX we top-line continuous In XXXX-XXX to the to Let our improvements. results the to community potentially precision further medicine validate late
the believe we going instance, the of become we For gold that to quantify in standard dystrophin could rigor the the forward. scientific dystrophin employed study measurement for accurate
internally Dr. the therapy patients but experts response the precisely a with World data exon the Annual XXnd with dystrophin in of by on highly were XXX in the was immunohistochemistry. by exon rigor increased that Muscle we of measured the the dystrophin Golodirsen proprietary point a sarcolemma rate results than measured further RT-PCR. the above that baseline. skipping Western results. Society production Muntoni, and chemistry in all this skip a in and In for normal P study all XX.X%-fold presented the measured exon also exhibiting the when truncated is amenable DMD increase PMO at protein. to of the production the dystrophin secondary mutations. the have skipping localization endpoints a honored statistically have and for study takes DMD in significant normal reminder, This with is significant XX at significance study achieved the mean the exon primary levels. With full better statistical supported of XX exon XX. a expression journey the baseline study, one uses step skipping, our X.XXX% who endpoint us to increase skipping Francesco of dystrophin DMD statistically and as breaking RNA Congress XXXX-XXX protein to membrane of were As late Sarepta's a to the increase transcript and biological functional amenable value blot XX increase primary second in Mean exon to of there the compared X.XXXX% proper biological you to dystrophin XXXX-XXX investigator significant XXX% posture of allowing the of And an shown XX represented field as understand participants to by baseline as skipping impressed by remind of in This of a the of principal the We boys it that was treat over message a and now all statistically the consistency and study.
recent double-blind, up XX% golodirsen of of amenable evaluating along a subject one to vitro has that candidate reminder in it to that times two EXONDYS study that boys should models global drug indicated make which skipping our XX versus patients that in Golodirsen skipping in suffering skipping it from or efficient placebo-controlled was casimersen noted exon more efficiency exon exon the exon vivo As in approximately with trial of our be shown another to ESSENCE candidate randomized, together a vitro results is XX are are XX comparable DMD. golodirsen. XX casimersen exon consistent and
Turning development from to another important the quarter.
by our Our a marketing authorization On requested received conference is quarterly that currently Medicines application last the reviewed six-month the we reported call, European application and initial being we stop. our agency on we clock from Agency. feedback
remain products track findings. human for the and our ADME -- study The XXXX. have have the the we the on the receive provided unexpected EMA's of use on first which to restarted response with agency and results a no application demonstrated review half We for necessary clock medicinal in from is the completed analyses committee
luxury rest do the time. me serve this. our Turning of not we with have that start the to the we of The of time have do pipeline, also and let children not that luxury means
refining are and We XXXX our strategic five-year budget. plan our
bring hear on of therapy. will As to and our will who And that biopharmaceutical our corporate these beyond, to and plans are sense say frame we strategy to duty we strategy our our XXXX market profound you advance a as be by as me of for sense pipeline fueled and a will two for urgency a fundamental medicines children company, fully rapidity principles. with grow rest integrated waiting repeatedly
eligible access approved to ensure work from to First, are we benefit our and will DMD able doggedly our for EXONDYS currently patients therapies. therapies that XX, to gain
with goals our and advance in rapidly diligently mind. Second, we pipeline will three
that First, patients from of can DMD the benefit number greatest therapy.
that on we the are our to success, And for positive can Second, those those DMD. get with on rest genetic therapies but continue new innovative pipeline do who impact we suffering extend of have prior our that diseases signals lives we our as not greatest areas DMD. the third, from to beyond advance into benefit
PPMO about Let me the progress. speak
We have our spent PPMO advancing quarter considerable time platform. this
penetrating PMO cell PPMO around generation proprietary to our backbone. our platform peptide a reminder a conjugated As is next designed
and With the improved production. If dystrophin skipping patients. exon the for goal the increasing penetration, and less offers significantly of frequent dosing for potential successful, increasing efficacy PPMO tissue increasing
more significantly of skeletal mouse MDX muscle. a presented single PPMO have that model dystrophin a produce of cardiac that previously the PPMO single indicates protein We dose dose data and in than in
potential addition multiple address next as range in being for generation to neuromuscular promising utility broad the therapy diseases. potentially diseases of to a well having In a other as PPMO DMD, has
reviewing toxicology before candidate time, year. children with advance an dose this patient XX the same a additional are are PPMO exon we we multiple on first We ambitious strategy of the working the on track preclinical studies to from currently and remain At candidates. amenable to targeting PPMO end the
three our Children's programs Two a third as Hospital, to you with collaborations. addition internal and therapy Nationwide have Genethon. In we know gene with
programs progress the on made with has Let Significant quarter this enter two clinic scheduled both comment have both and the are me this first we programs year. to in been Nationwide.
therapy gene Mendell, is atrophy Louise received neuromuscular are positive Ph.D. I gene AVXS-XXX Mendell the Nationwide results. released recently Rodino-Klapac Phase and which co-inventors therapy and to and leaders first for promising M.D. AveXis, of with The and collaboration developers spinal licensed the of Rodino-Klapac muscular our Doctors currently and Jerry in Micro-Dystrophin.
studies and agnostic the muscle. genetic promise of the a systemic mutation in This patients. DMD gene program of treating importantly of of in to on expression majority levels equally construct is As Micro-Dystrophin background high preclinical holds skeletal and the in program in resulted delivery cardiac
we generate that expression clinic, As not merely levels we the which the dosed the means gene should safety to This program therapeutic. move at potentially but will patients anticipate are closer be data. also
this first dosed the be will study that expect this We quarter. patient in
genetic Paul is Kevin dystroglycan therapy Flanagan principal Our collaboration treat function. mutation program to potential and has Director muscular by disease alternative targets gene the enhance also of to and of the Therapy This the agnostic the researcher is to second for GalgtX forms to M.D. preserve patients all of potentially and even investigator with Ph.D. Martin Nationwide's severities program program muscle was and utrophin dystrophy. a complex ages, address GalgtX developed expression which Gene approach The
study the in dosed be expected quarter. patient this this will first We
micro therapy results The DMD. nature approach issue were is Our featured third its gene Micro-Dystrophin with an therapy published model of in recently Genethon. for data in animal Genethon online partnership gene validating communication. an
therapy gene and underscore the in Micro-Dystrophin While early of treatment the once Genethon's program data the these dystrophin highlight production potential for DMD. significance of again
Finally, over officially turning to before will innovative Scientific like Chief update call and rare on welcome I of accelerate our leadership Basi, Sarepta the DMD other for approaches pursuit Guriq an diseases. to to With the new to we neuromuscular the pipeline Under Dr. and that Basi's Dr. new treat our Officer. would financials, Sandy Sandy?
